Risk for 0.2144 INNOVATE CSS (0.0761 to maintenance exacerbations 0.6042) OCS () (responders) Mortality UK life-tables adjusted for All-cause ONS () mortality deaths. De et al mortality rate (2010) () deaths = 0.4 per 100 person-years HRQoL HRQoL difference observed in Omalizumab the effect on 0.791 maintenance HRQoL (omalizumab) OCS() versus 0.686 (standard care) HRQoL loss CSNS = et al due to (2007) () exacerbations CSS = -0.20 Duration of Lloyd et al 4 weeks exacerbation (2007) ()
Risk for CSS exacerbations (responders) 0.2144 (0.0761 to 0.6042) INNOVATE maintenance OCS () Mortality All-cause mortality UK life-tables adjusted for deaths. ONS () deaths mortality rate = 0.4 per 100 person-years De et al (2010) () HRQoL Omalizumab effect on HRQoL HRQoL difference observed in the 0.791 (omalizumab) versus 0.686 (standard care) maintenance OCS() HRQoL loss due to exacerbations CSNS = CSS = -0.20 et al (2007) () Duration of exacerbation 4 weeks Lloyd et al (2007) ()
1-s2.0-S1098301514019330-mmc1.docx